Overall survival in patients with hormone receptor-positive, HER2

NEJM on X: DESTINY-Breast04: In a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician's choice of chemo among patients with HER2-low breast cancer. #ASCO22

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer, BMC Cancer

The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes - ScienceDirect

Targeted therapy for hormone receptor-positive breast cancer

Cancers, Free Full-Text

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial, Narui

HER2 Positive and Negative Breast Cancers: Aggressiveness, Treatment, and Survival